Eli Lilly's Sales Surge and Raised Guidance Driven by Mounjaro and Zepbound
TL;DR Summary
Eli Lilly's Q3 earnings surpassed expectations with $7.02 per share on $17.6 billion in sales, driven by strong sales of diabetes drug Mounjaro and weight-loss drug Zepbound, leading to an upward revision of annual guidance and a 3.9% rise in stock price.
- Eli Lilly Blows Past Expectations On The Back Of Mounjaro, Zepbound Investor's Business Daily
- Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar CNBC
- Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine statnews.com
- Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance Yahoo Finance
- Eli Lilly Stock Rises on Earnings and Boost to Guidance Barron's
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 2 min read
Condensed
84%
262 → 42 words
Want the full story? Read the original article
Read on Investor's Business Daily